<DOC>
	<DOCNO>NCT00223197</DOCNO>
	<brief_summary>The purpose research determine pregnenolone supplement associate reduction substance use crave patient recurrent major depressive disorder bipolar disorder substance abuse/dependence . This research also want explore pregnenolone supplement associate improvement psychiatric symptom memory , often negatively affected patient . It hypothesize patient receive pregnenolone supplement would show great improvement mood symptom memory , crave substance less patient receive placebo .</brief_summary>
	<brief_title>Pregnenolone Trial Depression Bipolar Disorders Recurrent Major Depressive Disorder With Substance Abuse</brief_title>
	<detailed_description>Seventy five - ( 75 ) outpatient meet inclusion exclusion criterion enrol complete IRB-approved informed consent process . Baseline evaluation include medical psychiatric history , structure clinical interview DSM-IV ( SCID ) , mood assessment Hamilton Rating Scale Depression ( HRSD , 17-item version ) , Inventory Depressive Symptomatology-Self Report ( IDS-SR ) ( Rush et al. , 1996 ) , Hamilton Rating Scale Anxiety ( HRSA ) , Young Mania Rating Scale ( YMRS ) , , cognitive assessment Rey Auditory Verbal Learning Test ( RAVLT ) , Stroop Test Color Trails , Wechsler Test Adult Reading Brief Visual Memory Test-Revised ( BVMT-R ) perform . Substance use ( days/week ) use , urine drug screen time relapse monitor . Craving substance monitor visual analogue scale . Pregnenolone placebo initiate one capsule/day ( 50 mg/d active medication ) . Pregnenolone placebo obtain Abrams Pharmacy , ensure potency ( supplier use GMP pharmaceutical standard ) . Participants return reassessment every 2 week 8 week HRSD , IDS-SR , YMRS , ISS , neurocognitive battery ( e.g . RAVLT , Stroop Test Trails B ) . Side effect monitor PRD-III Somatic Symptom Scale ( Thase et al. , 1996 ) . At week 4 subject significant side effect 50 % reduction HRSD score dosage increase two capsule per day ( 100 mg/d active medication ) . Participants pay $ 30 week 2 , 4 , 8 . Participants respond favorably , completion , option continue over-the-counter supplement choose physician 's knowledge approval .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>English speaking Diagnosis Bipolar I , II , NOS recurrent major depressive disorder Bipolar I patient must receive mood stabilizer History substancerelated disorder substance use within 14 day begin study Currently suicidal homicidal ( within 4 week study enrollment ) Severe lifethreatening medical illness Pregnant nursing female Current pregnenolone therapy allergies pregnenolone Member vulnerable population ( prisoner , demented , mental retardation ) Participants treatment resistant depression Actively psychotic within 2 month prior enrollment ; A change antipsychotic medication 1 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Bipolar depression</keyword>
	<keyword>Recurrent major depressive disorder</keyword>
	<keyword>substance abuse dependence</keyword>
</DOC>